|
Source
|
| Plastic
& Reconstructive Surgery

Volume:
107
Number: 2
Feb.
2001 |
|
TRAM
and DIEP Flaps
Gregory P. Reece, M.D.
In a review of the charts of 158 patients who had undergone breast
reconstruction with free transverse rectus abdominis musculocutaneous
(TRAM) or deepinferior epigastric perforator (DIEP) flaps and
who were treated for postoperative pain with morphine administered
by a patient-controlled analgesia pump, the total dose of morphine
administered during hospitalization for the flap transfer was
measured.
Patients
whose treatment was supplemented by other intravenous narcotics
were excluded from the study. The mean amount of morphine per
kilogram required by patients who had reconstruction with DIEP
flaps (0.74 mg/kg, n = 26) was found to be significantly
less than the amount required by patients who had reconstruction
with TRAM flaps (1.65 fig/kg; n = 132; p < 0.001).
DIEP flap patients also remained in the hospital less time (mean,
4.73 days) than did free TRAM flap patients (mean, 5.21 days;
p = 0.026), but the difference was less than one full hospital
day. It was concluded that the use of the DIEP flap does reduce
the patient requirement for postoperative pain medication and
therefore presumably reduces postoperative pain. It may also slightly
shorten hospital stay. (Plast. Reconstr. Surg. 107: 338,
2001.)
The deep inferior epigastric perforator (DIEP) flap is a relatively
new modification of the free transverse rectus abdominis musculocutaneous
(TRAM) flap in which branches of the deep inferior epigastric
artery and vein are dissected out of the rectus abdominis muscle
so that only blood vessels, and no muscle, are harvested with
the flap (Figs. 1 and 2) . In this way, donor-site morbidity is
minimized and postoperative pain is reduced. Patients recover
from the surgery more quickly and seem to require less pain medication.
With patient-controlled analgesia systems, patients control the
amount of narcotic pain medication so that they receive just enough
medication to control their postoperative pain but no more. To
avoid constipation and nausea, patients are motivated to minimize
the amount of narcotic used, and to increase their mobility, they
generally prefer to have the pump discontinued as soon as they
no longer need it. Consequently, the amount of narcotic medication
consumed by the patient can be considered a rough indicator of
the amount and duration of postoperative pain.
We decided to test the hypothesis that the DIEP flap causes less
postoperative pain than the standard free TRAM flap by measuring
the amount of narcotic medication used by each patient and comparing
the amounts used by patients who had reconstructions with different
types of flaps. We also wanted to see whether there was a difference
in the length of hospital stay and whether or not any difference
was either statistically or clinically significant.
Patients and Methods
All patients who underwent breast reconstruction at The University
of Texas M. D. Anderson Cancer Center with free TRAM or DIEP flaps
between March 1, 1996, and March 31, 2000, and who were treated
for postoperative pain with morphine administered by a patient-controlled
pump were eligible for the study. Virtually all patients who undergo
breast reconstruction in our institution are treated with narcotics,
using a patient-controlled pump. Morphine is usually the narcotic
of choice, but some patients do not tolerate morphine well and
are therefore given alternative drugs. Patients who had received
intravenous drugs other than morphine (such as Dilaudid or meperidine)
were excluded from this study, even if they had also received
morphine. Flap choice was determined by surgeon preference. Because
patient assignment to a surgeon was determined by a scheduling
nurse and was usually random, the choice of flap technique in
most cases was random as well. Patient charts were selected at
random for review, except that all eligible DIEP flaps performed
during the study period were included. The study was concluded
when enough patients had been accrued to allow valid comparisons
between the DIEP and free TRAM flap groups.
The mean dose of morphine (both in mg of morphine and in mg/kg)
was calculated for each group and comparisons made using the test
with independent samples. A two-way factorial analysis was also
performed using flap type and bilateral reconstruction to see
whether laterality affected the results. No other correction was
made for multiple testing. Differences with p values less
than 0.05 were considered to be statistically significant.
Results
During the study period, 158 patients' cases were reviewed.
No patients were excluded from the study because a patient-controlled
pump was not used, so use of the pump was universal and did not
bias our results. Of the reviewed patients, 26 had reconstructions
with DIEP flaps and 132 had reconstructions with free TRAM flaps
(Table 1) .
Patients who had reconstructions with DIEP flaps
used significantly less morphine (mean dose, 50.96 mg) than did
patients who had reconstructions with free TRAM flaps (mean dose;
1O7.04 mg; p < 0.001). Patients who had reconstructions
with DIEP flaps also used significantly less morphine per kilogram
(mean dose, 0.74 mg/kg) than did patients reconstructed with free
TRAM flaps (mean dose, 1.65 mg/kg; p < 0.001). Patients
who had reconstructions with DIEP flaps also had a mean hospital
stay (4.73 days) that was shorter than that of free TRAM flap
patients (5.21 days, p = 0.026) .
Patients who had unilateral reconstructions with
DIEP flaps (Table II) used significantly less morphine (mean dose,
54.25 mg) than did patients who had unilateral reconstructions
with free TRAM flaps (mean dose, 102.89 mg; p < 0.001).
They also used significantly less morphine per kilogram (mean
dose, 0.79 mg/kg) than did patients who underwent reconstructions
with free TRAM flaps (mean dose, 1.59 mg/kg; p = 0.002).
In patients who underwent unilateral reconstruction, those who
had DIEP flaps also had a mean hospital stay (4.71 days) that
was shorter than that of those who had free TRAM flaps (5.10 days),
but the difference was not statistically significant (p
= 0.077) .
The results in patients who had bilateral reconstructions
are listed in Table III. Patients with bilateral DIEP flaps required
far less morphine (mean dose, 11.50 mg) than did the patients
who underwent reconstructions with free TRAM flaps (mean dose,
120.55 mg), but because the sample of patients who had bilateral
reconstructions with DIEP flaps was so small, statistical analysis
was not attempted within this group. Morphine use was compared
between unilateral and bilateral free TRAM reconstructions, however.
In this comparison, women with bilateral reconstructions used
more morphine per kilogram (mean, 1.85 mg/kg) than did women with
unilateral reconstructions (mean, 1.59 mg/kg), but the difference
was not statistically significant (p = 0.246). A two-way
factorial analysis of morphine consumption per kilogram showed
that flap type was significantly associated with reduced morphine
use in this series (p = 0.001) but that unilateral reconstruction
was not (p = 0.621) .
Table I
Mean Postoperative Morphine Patient-Controlled Pump Use and Hospitalization
after Breast Reconstruction, by Type of Flap Used: All Patients
| |
Morphine
Dose |
Morphine
Dose |
Hospital
Stay |
| Flap Group |
No. of Patients |
Dose in mg |
SD |
Dose in mg/kg |
SD |
No. of Days |
SD |
| DIEP |
26 |
50.96 |
37.59 |
0.74 |
0.53 |
4.73 |
0.96 |
| Free TRAM |
132 |
107.04 |
73.05 |
1.65 |
1.03 |
5.21 |
0.99 |
Discussion
In our view, the DIEP flap is a special modification of the
free TRAM flap in which no muscle or fascia is killed and transferred
with the flap. Although some would argue that the DIEP flap is
in fact an entirely different type of flap because it is not musculocutaneous
in nature, it uses the same blood supply and skin paddle as the
free TRAM flap and is used for the same purposes. Moreover, there
is considerable variation in free TRAM flaps between those containing
the full width of the rectus abdominis muscle and fascia and those
containing only a small piece of muscle. The DIEP flap, for some
purposes, can therefore be considered as one end of a continuum
that contains all TRAM and DIEP flaps, notwithstanding its special
differences.
The DIEP flap has been advocated by many surgeons,
especially in Europe, as a way of performing autologous-tissue
breast reconstruction with less donor-site morbidity than other
types of TRAM flaps. The reduced morbidity is achieved by avoiding
sacrifice of any rectus abdominis muscle or fascia. In this way,
post- operative pain and abdominal weakness are minimized or avoided.
It is likely that relatively low tension on the fascial repair,
in particular, contributes significantly to the reduced postoperative
pain found in DIEP flap patients. The beneficial effect of not
removing fascia is increased by the absence of any need to plicate
the opposite side for symmetry.
This study confirms that patients who have had breast
reconstruction with DIEP flaps do have significantly less need
for postoperative pain medication than do patients who have had
standard free TRAM flaps. Differences in pain medication between
patients with the DIEP flap and those with the free TRAM flap
were highly significant, both statistically and clinically. This
confirms our impression that patients who undergo reconstruction
with DIEP flaps have less postoperative pain and recover more
rapidly from their surgery than do patients with TRAM flaps. The
differences were real and were noticed by patients, nurses, and
surgeons alike.
Table II
Mean Postoperative Morphine Patient-Controlled Pump Use and Hospitalization
after Breast Reconstruction, by Type of Flap Used: Unilateral
Reconstructions
| |
Morphine
Dose |
Morphine
Dose |
Hospital
Stay |
| Flap Group |
No. of Patients |
Dose in mg |
SD |
Dose in mg/kg |
SD |
No. of Days |
SD |
| DIEP |
24 |
54.25 |
37.22 |
0.79 |
0.53 |
4.71 |
0.95 |
| Free TRAM |
101 |
102.89 |
72.66 |
1.59 |
1.00 |
5.10 |
0.89 |
As expected, patients with bilateral TRAM flap reconstructions
needed more morphine than patients who had unilateral TRAM flap
reconstructions, but the differences did not reach statistical
significance, probably because of the small sample sizes. Interestingly,
pain medication use was not increased in patients who had bilateral
DIEP flaps, suggesting that the main source of pain in DIEP flap
patients may be in places other than the abdominal wall.
Patients who underwent reconstructions with DIEP
flaps tended to leave the hospital sooner than patients who underwent
reconstructions with standard free TRAM flaps, but the difference
was small. For all patients in this series, the difference in
hospital stay between the two groups was only 0.48 days. For unilateral
reconstructions (a more appropriate group to compare), the difference
was only 0.39 days. Although these differences are probably real
and might have reached statistical significance in a larger series,
the clinical (and financial) impact was relatively minor. Patients
with DIEP flaps. were kept in the hospital for at least 4 days
for flap monitoring even though they did not need hospitalization
for pain control, a fact that may well have minimized the difference
in length of hospital stay.
Table III
Mean Postoperative Morphine Patient-Controlled Pump Use and Hospitalization
after Breast Reconstruction, by Type of Flap Used: Bilateral Reconstructions
| |
Morphine
Dose |
|
| Flap Group |
No. of Patients |
Dose in mg |
mg/kg |
Days In Hospital |
| DIEP |
2 |
11.50 |
0.16 |
5.00 |
| Free TRAM |
31 |
120.55 |
1.85 |
5.58 |
This report supports the efficacy of the DIEP flap in reducing
abdominal donor-site morbidity. It should not imply, however,
that all other types of TRAM flaps are obsolete or inferior to
the DIEP flap. The DIEP flap causes less donor-site morbidity,
but it also is supplied by fewer perforators and therefore has
less blood supply than the usual free TRAM flap. For some patients,
the DIEP flap may well be the method of choice. For others, those
who require a more robust flap blood supply, other flaps may be
preferred. This subject, however, is beyond the scope of this
article and will be covered in a separate report.
In conclusion, our data suggest that the DIEP flap
does in fact cause less postoperative pain than other types of
TRAM flaps. As such, it has real advantages and deserves serious
consideration by surgeons who perform postmastectomy breast reconstruction
with autologous tissues.
References
1. Koshima, I., and Soeda, S. Inferior epigastric artery
skin flaps without rectus abdominis muscle. Br. J. Plast.
Surg. 42: 645, 1989.
2. Allen, R. J., and Treece, P. Deep inferior epigastric
perforator flap for breast reconstruction. Ann. Plast. Surg.
32: 32, 1994.
3. Blondeel, P. N., and Boeckx, W. D. Refinements in
free flap breast reconstruction: The free bilateral deep inferior
epigastric perforator flap anastomosed to the internal mammary
artery. Br. J. Plast. Surg. 47: 495, 1994.
4. Blondeel, P. N., One hundred free DIEP flap breast
reconstructions: A personal experience. Br. J. Plast. Surg.
52: 104, 1999.
5. Hamdi, M., Weiler-Mithoff, E. M., and Webster , M. H. C.
Deep inferior epigastric perforator flap in breast reconstruction:
Experience with the first 50 flaps. Plast. Reconstr. Surg.
103: 86, 1999.
6. Feller, A. M., and Galla, T. J. The deep inferior
epigastric artery perforator flap. Clin. Plas. Surg. 25:
197, 1998.
7. Blondeel, P. N., Van Landuyt, K., and Monstrey, S. J.
Surgical-technical aspects of the free DIEP flap for breast
reconstruction. Oper. Techn. Plast. Reconstr. Surg. 6: 27, 1999.